Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
uniQureN. V. develops treatments for patients suffering from rare and other devastating diseases.
It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B.
The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease.
The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 5, 24 | -0.84 Increased by +55.54% | -0.93 Increased by +9.77% |
| Aug 1, 24 | -1.16 Increased by +19.44% | -1.25 Increased by +7.20% |
| May 7, 24 | -1.36 Increased by +16.56% | -1.28 Decreased by -6.25% |
| Feb 28, 24 | -1.53 Decreased by -1.12 K% | -1.46 Decreased by -4.79% |
| Nov 7, 23 | -1.88 Decreased by -84.31% | -0.85 Decreased by -121.18% |
| Aug 1, 23 | -1.44 Decreased by -71.43% | 2.05 Decreased by -170.24% |
| May 9, 23 | -1.63 Decreased by -63.00% | -0.95 Decreased by -71.58% |
| Feb 27, 23 | 0.15 Decreased by -11.76% | -0.89 Increased by +116.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 2.29 M Increased by +62.54% | -44.38 M Increased by +50.45% | Decreased by -1.94 K% Increased by +69.52% |
| Jun 30, 24 | 11.13 M Increased by +359.37% | -56.30 M Increased by +17.78% | Decreased by -506.01% Increased by +82.10% |
| Mar 31, 24 | 8.48 M Increased by +59.34% | -65.62 M Increased by +15.03% | Decreased by -773.34% Increased by +46.68% |
| Dec 31, 23 | 6.69 M Decreased by -93.49% | -73.21 M Decreased by -1.18 K% | Decreased by -1.09 K% Decreased by -16.62 K% |
| Sep 30, 23 | 1.41 M Decreased by -2.90% | -89.57 M Decreased by -87.16% | Decreased by -6.37 K% Decreased by -92.75% |
| Jun 30, 23 | 2.42 M Increased by +387.32% | -68.47 M Decreased by -75.30% | Decreased by -2.83 K% Increased by +64.03% |
| Mar 31, 23 | 5.33 M Increased by +197.15% | -77.23 M Decreased by -65.45% | Decreased by -1.45 K% Increased by +44.32% |
| Dec 31, 22 | 102.75 M Increased by +78.10% | 6.81 M Decreased by -17.07% | Increased by +6.63% Decreased by -53.43% |